NA Lymphedema Treatment Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 MULTIVARIATE MODELLING 53
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET APPLICATION COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 64
4.1 PESTEL'S ANALYSIS 66
4.2 PORTER'S MODEL 67
5 PIPELINE ANALYSIS FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 68
6 EPIDEMIOLOGY 69
7 REGULATORY GUIDELINES FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 70
7.1 U.S. 70
7.2 EUROPE 71
7.3 INDIA 71
7.4 MEXICO 72
7.5 CANADA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES NORTH AMERICALY 76
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 76
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 77
8.1.4 MULTIPLE THERAPIES 77
8.2 RESTRAINTS 78
8.2.1 HIGH COST OF TREATMENT 78
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 79
8.3 OPPORTUNITIES 79
8.3.1 DRUG APPROVALS 79
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 80
8.4 CHALLENGES 80
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 80
8.4.2 DIFFICULT REIMBURSEMENT 81
9 IMPACT OF COVID-19 ON THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 82
9.1 IMPACT ON PRICE 82
9.2 IMPACT ON DEMAND 82
9.3 IMPACT ON SUPPLY CHAIN 83
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS 83
9.5 CONCLUSION 83
10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 85
10.1 OVERVIEW 86
10.2 COMPRESSION THERAPY 89
10.2.1 BY PRODUCT 89
10.2.1.1 COMPRESSION PUMPS 89
10.2.1.2 COMPRESSION GARMENTS 89
10.2.1.2.1 COMPRESSION STOCKINGS 90
10.2.1.2.2 COMPRESSION SLEEVES 90
10.2.1.2.3 OTHERS 90
10.2.1.3 COMPRESSION BANDAGES & WRAPS 90
10.2.1.4 OTHERS 90
10.2.2 BY TECHNIQUE 91
10.2.2.1 STATIC COMPRESSION THERAPY 91
10.2.2.2 DYNAMIC COMPRESSION THERAPY 91

10.3 SURGERY 91
10.3.1 LYMPHOVENOUS TRANSPLANT 92
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS 92
10.3.3 LIPOSUCTION 92
10.3.4 OTHERS 92
10.4 DRUG THERAPY 92
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 93
10.4.2 RETINOIDS 93
10.4.3 ANTIBIOTICS 93
10.4.4 OTHERS 93
10.5 LASER THERAPY 94
10.6 OTHERS 95
11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE 96
11.1 OVERVIEW 97
11.2 SECONDARY LYMPHEDEMA 100
11.3 PRIMARY LYMPHEDEMA 100
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 101
11.3.2 CONGENITAL LYMPHEDEMA 101
11.3.3 LYMPHEDEMA TARDA 101
12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 102
12.1 OVERVIEW 103
12.2 LOWER EXTREMITY 106
12.3 UPPER EXTREMITY 106
12.4 GENITALIA 107
13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 108
13.1 OVERVIEW 109
13.2 ADULT 112
13.3 GERIATRIC 112
13.4 PEDIATRIC 113
14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 114
14.1 OVERVIEW 115
14.2 ORAL 118
14.3 INJECTABLE 118
14.4 TOPICAL 119

15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER 120
15.1 OVERVIEW 121
15.2 HOSPITAL 124
15.3 SPECIALTY CLINICS 124
15.4 AMBULATORY SURGICAL CENTERS 125
15.5 OTHERS 125
16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 126
16.1 OVERVIEW 127
16.2 PHARMACY STORES 130
16.3 DIRECT TENDER 130
16.4 OTHERS 131
17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION 132
17.1 NORTH AMERICA 133
17.1.1 U.S. 141
17.1.2 CANADA 144
17.1.3 MEXICO 147
18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE 151
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 151
19 SWOT ANALYIS 152
20 COMPANY PROFILE 153
20.1 TACTILE MEDICAL 153
20.1.1 COMPANY SNAPSHOT 153
20.1.2 REVENUE ANALYSIS 153
20.1.3 COMPANY SHARE ANALYSIS 154
20.1.4 PRODUCT PORTFOLIO 154
20.1.5 RECENT DEVELOPMENT 154
20.1.6 CLINICAL TRIAL: 154
20.2 ESSITY (BSN MEDICAL GMBH) 155
20.2.1 COMPANY SNAPSHOT 155
20.2.2 COMPANY SHARE ANALYSIS 155
20.2.3 PRODUCT PORTFOLIO 155
20.2.4 RECENT DEVELOPMENT 156

20.3 3M 157
20.3.1 COMPANY SNAPSHOT 157
20.3.2 REVENUE ANALYSIS 157
20.3.3 COMPANY SHARE ANALYSIS 158
20.3.4 PRODUCT PORTFOLIO 158
20.3.5 RECENT DEVELOPMENTS 158
20.3.6 NEW BUSINESS SEGMENT 158
20.3.7 ACQUISITION 159
20.4 CARDINAL HEALTH 160
20.4.1 COMPANY SNAPSHOT 160
20.4.2 REVENUE ANALYSIS 160
20.4.3 COMPANY SHARE ANALYSIS 161
20.4.4 PRODUCT PORTFOLIO 161
20.4.5 RECENT DEVELOPMENT 161
20.5 LOHMANN & RAUSCHER GMBH & CO. KG 162
20.5.1 COMPANY SNAPSHOT 162
20.5.2 COMPANY SHARE ANALYSIS 162
20.5.3 PRODUCT PORTFOLIO 163
20.5.4 RECENT DEVELOPMENT 163
20.6 AIROS MEDICAL, INC. 164
20.6.1 COMPANY SNAPSHOT 164
20.6.2 PRODUCT PORTFOLIO 164
20.6.3 RECENT DEVELOPMENT 164
20.6.4 PRODUCT LAUNCH: 164
20.7 AVET PHARMACEUTICALS INC. 165
20.7.1 COMPANY SNAPSHOT 165
20.7.2 PRODUCT PORTFOLIO 165
20.7.3 RECENT DEVELOPMENT 165
20.8 BIOCOMPRESSION SYSTEMS 166
20.8.1 COMPANY SNAPSHOT 166
20.8.2 PRODUCT PORTFOLIO 166
20.8.3 RECENT DEVELOPMENT 167
20.8.4 AGREEMENT 167
20.9 CONVATEC INC. 168
20.9.1 COMPANY SNAPSHOT 168
20.9.2 PRODUCT PORTFOLIO 168
20.9.3 RECENT DEVELOPMENT 168
20.10 HERANTIS PHARMA PLC 169
20.10.1 COMPANY SNAPSHOT 169
20.10.2 RECENT DEVELOPMENT 169
20.11 HUNTLEIGH HEALTHCARE LIMITED 170
20.11.1 COMPANY SNAPSHOT 170
20.11.2 PRODUCT PORTFOLIO 170
20.11.3 RECENT DEVELOPMENT 170
20.12 JUZO 171
20.12.1 COMPANY SNAPSHOT 171
20.12.2 PRODUCT PORTFOLIO 171
20.12.3 RECENT DEVELOPMENT 171
20.13 KOYA MEDICAL 172
20.13.1 COMPANY SNAPSHOT 172
20.13.2 PRODUCT PORTFOLIO 172
20.13.3 RECENT DEVELOPMENT 172
20.13.4 APPROVAL 172
20.14 MEDI GMBH & CO. KG 173
20.14.1 COMPANY SNAPSHOT 173
20.14.2 PRODUCT PORTFOLIO 173
20.14.3 RECENT DEVELOPMENT 173
20.15 MEGO AFEK LTD 174
20.15.1 COMPANY SNAPSHOT 174
20.15.2 PRODUCT PORTFOLIO 174
20.15.3 RECENT DEVELOPMENT 175
20.15.4 APPLICATION LAUNCH: 175
20.16 PAUL HARTMANN AG 176
20.16.1 COMPANY SNAPSHOT 176
20.16.2 REVENUE ANALYSIS 176
20.16.3 PRODUCT PORTFOLIO 177
20.16.4 RECENT DEVELOPMENTS 177
20.17 SANYLEG SRL A SOCIO UNICO 178
20.17.1 COMPANY SNAPSHOT 178
20.17.2 PRODUCT PORTFOLIO 178
20.17.3 RECENT DEVELOPMENT 178
20.18 SIGVARIS GROUP 179
20.18.1 COMPANY SNAPSHOT 179
20.18.2 PRODUCT PORTFOLIO 179
20.18.3 RECENT DEVELOPMENTS 180
20.18.4 PRODUCT LAUNCHES: 180
20.19 SMITH +NEPHEW 181
20.19.1 COMPANY SNAPSHOT 181
20.19.2 REVENUE ANALYSIS 181
20.19.3 PRODUCT PORTFOLIO 182
20.19.4 RECENT DEVELOPMENT 182
20.20 THERMOTEK 183
20.20.1 COMPANY SNAPSHOT 183
20.20.2 PRODUCT PORTFOLIO 183
20.20.3 RECENT DEVELOPMENT 183
21 QUESTIONNAIRE 184
22 RELATED REPORTS 188